{"product_id":"mitochondrial-dysfunction-caused-by-drugs-and-environmental-toxicants-isbn-9781119329701","title":"Mitochondrial Dysfunction Caused by Drugs and Environmental Toxicants","description":"Developed as a one-stop reference source for drug safety and toxicology professionals, this book explains why mitochondrial failure is a crucial step in drug toxicity and how it can be avoided. \u003cbr\u003e\u003cbr\u003e•    Covers both basic science and applied technology \/ methods\u003cbr\u003e•    Allows readers to understand the basis of mitochondrial function, the preclinical assessments used, and what they reveal about drug effects\u003cbr\u003e•    Contains both in vitro and in vivo methods for analysis, including practical screening approaches for drug discovery and development\u003cbr\u003e•    Adds coverage about mitochondrial toxicity underlying organ injury, clinical reports on drug classes, and discussion of environmental toxicants affecting mitochondria \u003cp\u003e\u003cb\u003eVolume 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eList of Contributors xvii\u003c\/p\u003e \u003cp\u003eForeword xxix\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Basic Concepts 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Contributions of Plasma Protein Binding and Membrane Transporters to Drug]Induced Mitochondrial Toxicity 3\u003cbr\u003e\u003ci\u003eGavin P. McStay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 The Role of Transporters in Drug Accumulation and Mitochondrial Toxicity 15\u003cbr\u003e\u003ci\u003eKathleen M. Giacomini and Huan]Chieh Chien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Modeling of Mitochondrial Dysfunction 25\u003cbr\u003e\u003ci\u003eSteve Enoch, Claire Mellor, and Mark Nelms\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Mitochondria]Targeted Cytochromes P450 Modulate Adverse Drug Metabolism and Xenobiotic Induced Toxicity 35\u003cbr\u003e\u003ci\u003eHaider Raza, F. Peter Guengerich, and Narayan G. Avadhani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Organ Drug Toxicity: Mitochondrial Etiology 47\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5 Mitochondrial Dysfunction in Drug]Induced Liver Injury 49\u003cbr\u003e\u003ci\u003eAnnie Borgne]Sanchez and Bernard Fromenty\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Evaluating Mitotoxicity as Either a Single or Multi]Mechanistic Insult in the Context of Hepatotoxicity 73\u003cbr\u003e\u003ci\u003eAmy L. Ball, Laleh Kamalian, Carol E. Jolly, and Amy E. Chadwick\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Cardiotoxicity of Drugs: Role of Mitochondria 93\u003cbr\u003e\u003ci\u003eZoltan V. Varga and Pal Pacher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Skeletal Muscle Mitochondrial Toxicity 111\u003cbr\u003e\u003ci\u003eEric K. Herbert, Saul R. Herbert, and Karl E. Herbert\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Manifestations of Drug Toxicity on Mitochondria in the Nervous System 133\u003cbr\u003e\u003ci\u003eJochen H. M. Prehn and Irene Llorente]Folch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Nephrotoxicity: Increasing Evidence for a Key Role of Mitochondrial Injury and Dysfunction and Therapeutic Implications 169\u003cbr\u003e\u003ci\u003eAna Belén Sanz, Maria Dolores Sanchez]Niño, Adrian M. Ramos, and Alberto Ortiz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Mammalian Sperm Mitochondrial Function as Affected by Environmental Toxicants, Substances of Abuse, and Other Chemical Compounds 185\u003cbr\u003e\u003ci\u003eSandra Amaral, Renata S. Tavares, Sara Escada]Rebelo, Andreia F. Silva, and João Ramalho]Santos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Methods to Detect Mitochondrial Toxicity: In Vitro, Ex Vivo, In Vivo, Using Cells, Animal Tissues,\u003c\/b\u003e \u003cb\u003eand Alternative Models 205\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12 Biological and Computational Techniques to Identify Mitochondrial Toxicants 207\u003cbr\u003e\u003ci\u003eRobert B. Cameron, Craig C. Beeson, and Rick G. Schnellmann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 The Parallel Testing of Isolated Rat Liver and Kidney Mitochondria Reveals a Calcium]Dependent Sensitivity to Diclofenac and Ibuprofen 217\u003cbr\u003e\u003ci\u003eSabine Schulz, Sabine Borchard, Tamara Rieder, Carola Eberhagen, Bastian Popper, Josef\u003c\/i\u003e \u003ci\u003eLichtmannegger, Sabine Schmitt, and Hans Zischka\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 In Vitro Methodologies to Investigate Drug]Induced Toxicities 229\u003cbr\u003e\u003ci\u003eRui F. Simões, Teresa Cunha]Oliveira, Cláudio F. Costa, Vilma A. Sardão, and Paulo J. Oliveira\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Combined Automated Measurement of Respiratory Chain Complexes and Oxidative Stress: A First Step to an Integrated View of Cell Bioenergetics 249\u003cbr\u003e\u003ci\u003eMarc Conti, Thierry Delvienne, and Sylvain Loric\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Measurement of Mitochondrial Toxicity by Flow Cytometry 265\u003cbr\u003e\u003ci\u003ePadma Kumar Narayanan and Nianyu Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 MitoChip: A Transcriptomics Tool for Elucidation of Mechanisms of Mitochondrial Toxicity 275\u003cbr\u003e\u003ci\u003eVarsha G. Desai, and G. Ronald Jenkins\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Using 3D Microtissues for Identifying Mitochondrial Liabilities 295\u003cbr\u003e\u003ci\u003eSimon Messner, Olivier Frey, Katrin Rössger, Andy Neilson, and Jens M. Kelm\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Toward Mitochondrial Medicine: Challenges in Rodent Modeling of Human Mitochondrial Dysfunction 305\u003cbr\u003e\u003ci\u003eDavid A. Dunn, Michael H. Irwin, Walter H. Moos, Kosta Steliou, and Carl A. Pinkert\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Measurement of Oxygen Metabolism In Vivo 315\u003cbr\u003e\u003ci\u003eM. P. J. van Diemen, R. Ubbink, F. M. Münker, E. G. Mik, and G. J. Groeneveld\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Detection of Mitochondrial Toxicity Using Zebrafish 323\u003cbr\u003e\u003ci\u003eSherine S. L. Chan and Tucker Williamson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 MiRNA as Biomarkers of Mitochondrial Toxicity 347\u003cbr\u003e\u003ci\u003eTerry R. Van Vleet and Prathap Kumar Mahalingaiah\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Biomarkers of Mitochondrial Injury After Acetaminophen Overdose: Glutamate Dehydrogenase and Beyond 373\u003cbr\u003e\u003ci\u003eBenjamin L. Woolbright and Hartmut Jaeschke\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Acylcarnitines as Translational Biomarkers of Mitochondrial Dysfunction 383\u003cbr\u003e\u003ci\u003eRichard D. Beger, Sudeepa Bhattacharyya, Pritmohinder S. Gill, and Laura P. James\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Mitochondrial DNA as a Potential Translational Biomarker of Mitochondrial Dysfunction in Drug]Induced Toxicity Studies 395\u003cbr\u003e\u003ci\u003eAfshan N. Malik\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Predicting Off]Target Effects of Therapeutic Antiviral Ribonucleosides: Inhibition of Mitochondrial RNA Transcription 407\u003cbr\u003e\u003ci\u003eJamie J. Arnold and Craig E. Cameron\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Imaging of Mitochondrial Toxicity in the Kidney 419\u003cbr\u003e\u003ci\u003eAndrew M. Hall, Joana R. Martins, and Claus D. Schuh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Imaging Mitochondrial Membrane Potential and Inner Membrane Permeability 429\u003cbr\u003e\u003ci\u003eAnna]Liisa Nieminen, Venkat K. Ramshesh, and John J. Lemasters\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Quantifying Skeletal Muscle Mitochondrial Function In Vivo by 31P Magnetic Resonance Spectroscopy 443\u003cbr\u003e\u003ci\u003eGraham J. Kemp\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003eVolume 2\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eList of Contributors xiii\u003c\/p\u003e \u003cp\u003eForeword xxv\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Reports from the Clinic 457\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e30 Statin and Fibrate]Induced Dichotomy of Mitochondrial Function 459\u003cbr\u003e\u003ci\u003eViruna Neergheen, Alex Dyson, Luke Wainwright, and Iain P. Hargreaves\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Friend or Foe: Can Mitochondrial Toxins Lead to Similar Benefits as Exercise? 475\u003cbr\u003e\u003ci\u003eSofia Annis, Adeel Safdar, Eduardo Biala, Ayesha Saleem, Housaiyin Li, Priya Gandhi, Zoe Fleischmann,\u003c\/i\u003e \u003ci\u003eCarmen Castaneda]Sceppa, Jonathan L. Tilly, Dori C. Woods, and Konstantin Khrapko\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Involvement of Mitochondrial Dysfunction on the Toxic Effects Caused by Drugs of Abuse and Addiction 487\u003cbr\u003e\u003ci\u003eDaniel José Barbosa, João Paulo Capela, Maria de Lourdes Bastos, and Félix Carvalho\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Drug]Induced Mitochondrial Toxicity during Pregnancy 509\u003cbr\u003e\u003ci\u003eDiana Luz Juárez-Flores, Ana Sandra Hernández, Laura Garcia, Mariona Guitart]Mampel, Marc Catalan]Garcia, Ingrid Gonzalez]Casacuberta, Jose César Milisenda, Josep Maria Grau, Francesc Cardellach,\u003c\/i\u003e \u003ci\u003eConstanza Morén, and Glòria Garrabou\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Mitochondrial Toxicity in Children and Adolescents Exposed to Antiretroviral Therapy 521\u003cbr\u003e\u003ci\u003eAntoni Noguera]Julian, Eneritz Velasco]Arnaiz, and Clàudia Fortuny\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Drug]Induced Mitochondrial Cardiomyopathy and Cardiovascular Risks in Children 529\u003cbr\u003e\u003ci\u003eNeha Bansal, Mariana Gerschenson, Tracie L. Miller, Stephen E. Sallan, Jason Czachor, Hiedy Razoky,\u003c\/i\u003e \u003ci\u003eAshley Hill, Miriam Mestre, and Steven E. Lipshultz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Role of Mitochondrial Dysfunction in Linezolid]Induced Lactic Acidosis 547\u003cbr\u003e\u003ci\u003eAlessandro Santini, Dario Ronchi, Daniela Piga, and Alessandro Protti\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Metformin and Lactic Acidosis 559\u003cbr\u003e\u003ci\u003eJean]Daniel Lalau\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 Lessons Learned from a Phase I Clinical Trial of Mitochondrial Complex I Inhibition 563\u003cbr\u003e\u003ci\u003eCecilia C. Low Wang, Jeffrey L. Galinkin, and William R. Hiatt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e39 Pharmacological Activation of Mitochondrial Biogenesis for the Treatment of Various Pathologies 569\u003cbr\u003e\u003ci\u003eWhitney S. Gibbs, Natalie E. Scholpa, Craig C. Beeson, and Rick G. Schnellmann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e40 Mitochondrial Toxicity Induced by Chemotherapeutic Drugs 593\u003cbr\u003e\u003ci\u003eLuciana L. Ferreira, Ana Raquel Coelho, Paulo J. Oliveira, and Teresa Cunha]Oliveira\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5 Environmental Toxicants and Mitochondria 613\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e41 The Mitochondrial Exposome 615\u003cbr\u003e\u003ci\u003eDouglas I. Walker, Kurt D. Pennell, and Dean P. Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Central Mitochondrial Signaling Mechanisms in Response to Environmental Agents: Integrated Omics for Visualization 639\u003cbr\u003e\u003ci\u003eYoung]Mi Go, Karan Uppal, and Dean P. Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e43 Detection of Mitochondrial Toxicity of Environmental Pollutants Using Caenorhabditis elegans 655\u003cbr\u003e\u003ci\u003eLaura L. Maurer, Anthony L. Luz, and Joel N. Meyer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e44 Persistent Organic Pollutants, Mitochondrial Dysfunction, and Metabolic Syndrome 691\u003cbr\u003e\u003ci\u003eHong Kyu Lee and Youngmi Kim Pak\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e45 Cigarette Smoke and Mitochondrial Damage 709\u003cbr\u003e\u003ci\u003eJalal Pourahmad, Marjan Aghvami, Mohammad Hadi Zarei, and Parvaneh Naserzadeh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 727\u003c\/p\u003e \u003cp\u003e\u003cb\u003eYvonne Will, PhD,\u003c\/b\u003e is a Senior Director and the Head of Science and Technology Strategy, Drug Safety Research and Development at Pfizer, Connecticut, USA. In addition to the prior edition of this book, she co-edited \u003ci\u003eDrug Discovery Toxicology: From Target Assessment to Translational Biomarkers\u003c\/i\u003e(Wiley, 2016).\u003c\/p\u003e \u003cb\u003eJames A. Dykens, PhD,\u003c\/b\u003e oversees EyeCyte Therapeutics, a start-up developing treatments for progressive blinding diseases via targeting mitochondrial dysfunction. He co-edited the first edition of this book. \u003cp\u003eA major public health concern, despite regulatory vigilance, is untoward toxicity and other pharmaceutical side effects. This toxicity is often idiosyncratic, and usually not discovered until after a large population has been exposed and injured. Recent laboratory evaluations show that many of these drugs impact mitochondrial function. The realization that mitochondrial toxicity is a widespread and important issue in drug toxicity is increasingly appreciated, and most pharmaceutical companies now either have the technology to assess this risk themselves, or do so via contract research organizations.\u003c\/p\u003e \u003cp\u003eDeveloped as a one-stop reference source for drug safety and toxicology professionals, the  second edition of \u003ci\u003eDrug and Environmental Induced Mitochondrial Dysfunction\u003c\/i\u003e explains why mitochondrial failure is a crucial step in drug toxicity and how it can be avoided. It allows readers to understand the basis of mitochondrial function and the preclinical assessments used and what they reveal about drug effects. The focus is on how the requisite technology continues to evolve and the recent emergence of clinical techniques capable of detecting drug-induced mitochondrial toxicity in patients.\u003c\/p\u003e \u003cp\u003eAdded coverage in the 2nd edition includes how and why mitochondrial toxicity underlies organ injury, clinical reports on drug classes, and discussion of environmental toxicants that can affect mitochondria. With chapters contributed by leading specialists in their areas, \u003ci\u003eDrug and Environmental Induced Mitochondrial Dysfunction\u003c\/i\u003e, \u003ci\u003e2nd Edition \u003c\/i\u003econtinues to serve as a valuable resource for safety assessment professionals in the pharmaceutical industry – including bench scientists and managers – and for pharmacologists and toxicologists in both drug and environmental health sciences.\u003cbr\u003e\u003cbr\u003e\u003ci\u003eDrug and Environmental Induced Mitochondrial Dysfunction \u003c\/i\u003eprovides ample reminders of the intimate connections between mitochondria, pharmacology, and toxicology.  The book takes a rather systematic approach to mitochondrial pharmacology and toxicology and, for this reason, will be of use to even those outside of strict drug discovery.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989632106725,"sku":"NP9781119329701","price":404.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119329701.jpg?v=1761784885","url":"https:\/\/k12savings.com\/products\/mitochondrial-dysfunction-caused-by-drugs-and-environmental-toxicants-isbn-9781119329701","provider":"K12savings","version":"1.0","type":"link"}